MeiraGTx Holdings plc (MGTX)
- Previous Close
5.23 - Open
5.36 - Bid 5.44 x 200
- Ask 5.57 x 400
- Day's Range
5.36 - 5.57 - 52 Week Range
3.49 - 8.35 - Volume
32,413 - Avg. Volume
143,067 - Market Cap (intraday)
354.008M - Beta (5Y Monthly) 1.31
- PE Ratio (TTM)
-- - EPS (TTM)
-1.19 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.20
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
meiragtx.comRecent News: MGTX
Performance Overview: MGTX
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MGTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGTX
Valuation Measures
Market Cap
336.32M
Enterprise Value
305.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.73
Price/Book (mrq)
2.76
Enterprise Value/Revenue
26.84
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.82%
Return on Equity (ttm)
-69.93%
Revenue (ttm)
11.38M
Net Income Avi to Common (ttm)
-74.11M
Diluted EPS (ttm)
-1.19
Balance Sheet and Cash Flow
Total Cash (mrq)
119.21M
Total Debt/Equity (mrq)
72.60%
Levered Free Cash Flow (ttm)
-84.57M
Research Analysis: MGTX
Company Insights: MGTX
MGTX does not have Company Insights